Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Local newcomer aims to break into Nordic generic market dominated by multinationals

This article was originally published in Scrip

Executive Summary

A company that has set itself the target of becoming the fifth largest generics player in the Nordic region by 2015 has launched its first two products. Norwegian firm Navamedic, which last year signed a deal with the major generics producer Aspen of South Africa giving it exclusive rights to sell Aspen products in the Nordic and Benelux markets, has launched the immunosuppressant mycophenolate mofetil in Sweden, Denmark and Finland, and the antipsychotic olanzapine in Finland and the Netherlands.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014797

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel